Celtarys is a newly created company focused on the development of innovative chemical tools that improve the efficiency of the High Throughput Screening (HTS) process in early drug discovery:
Our proprietary technology allows the synthesis of fluorescent ligands with excellent performance features in terms of affinity, potency and selectivity that can be used in a variety of biological assays, from competitive binding assays to microscopy or kinetic studies.
Celtarys is a spin-off of the University of Santiago de Compostela.
Our patented proprietary technology is based on the scientific work of the research group of Prof. Eddy Sotelo, which combines a long-tracked expertise in medicinal chemistry & chemical biology with a deep knowledge of GPCR structure.
We count also with the expertise in pharmacology and HTS of the group of Prof. Mabel Loza, a worldwide leader in early drug discovery collaborative projects with pharma companies.
Celtarys has a multidisciplinary and balanced team with different profiles that provide expert knowledge in each area necessary to develop and market novel products, designed from the real unmet needs in the complex early drug discovery scenario.
Co-founder and Scientific Leader
Eddy is Professor of Organic & Medicinal Chemistry at the University of Santiago de Compostela (USC). He studied Chemistry at the University of Habana (BSc, 1993) and undertook PhD studies in Medicinal Chemistry at the USC (1995-2000). After postdoctoral studies in Bari and Barcelona (2003-2005), he joined the Institute of Industrial Pharmacy of the USC (2006-2010) and in 2011 was appointed as associate professor. In 2015 Eddy awarded the prestigious Salvador de Madariaga mobility grant for a stay as a visiting professor at the University of Cambridge (Department of Chemistry).
His group is involved in discovering novel drugs and molecular probes that target GPCRs (https://www.sotelolab.es) with an emphasis on contemporary GPCR concepts (e.g., GPCR oligomerization, biased signaling and allosteric modulation). He has published over 100 papers and several book chapters, being the principal investigator of 11 research projects and 20 collaborative research contracts with biotech companies. Eddy and his team developed the proprietary synthetic methodology laying the groundwork of the Celtarys company.
Co-founder and CSO (Chief Scientific Officer)
After a degree in Pharmaceutical Chemistry and Technology in the University of Bari (Italy), she earned her PhD as “Doctor Europeus” in “Biomolecular Sciences in Pharmacology and Medicine” in 2018. Since 2018, she works in the University of Santiago de Compostela as Post-doctoral research associate, in the group of Prof. Eddy Sotelo.
Her scientific expertise is focused on organic synthesis and medicinal chemistry, especially in the field of GPCR ligands. She has strongly contributed to the development and validation of the Celtarys proprietary synthetic technology, taking part directly in the creation of the company
Sonia Martínez Arca
Co-founder and CEO
With a scientific background – Bachelor of Science in Pharmacy and PhD in Molecular and Cellular Biology- she has developed a classic research career for more than ten years, in Spanish and European centers – Centro de Biología Molecular Severo Ochoa (Madrid), Curie Institute (Paris), Vall d’Hebron Hospital (Barcelona).
Since 2005 she is dedicated to research and innovation management. She has held leading positions in this field at the Barcelona Science Park, the University of Santiago de Compostela, the IDIS Foundation of the University Clinical Hospital of Santiago and the regional Ministry of Health in Galicia. Since 2018 she is focused on start-up acceleration and entrepreneurship. Celtarys is the second spin-off she leads, after a successful experience with another knowledge-based company, Sigillum Knowledge Solutions.
During his PhD at the Polytechnic University of Madrid, Alessandro consolidated his knowledge in Molecular biology and Biophysics, working in the characterization of the nitrogenase enzyme and its possible genetic transposition to eukaryotic organisms for a project financed by Melinda and Bill Gates. Since 2015, Alessandro has accumulated a wide range of international experiences, working in different commercial and management roles for different life sciences companies such as Merck group, Abcam, Novoptim and Bio-techne.
Along his path, Alessandro has also worked as business developer for numerous start-up (Lume, IDEA Biomedical and Startquake S.L.), defining their market and technology road map. Thanks to this multidisciplinary experience, Alessandro is responsible in the definition of the marketing strategy and product market penetration at Celtarys Research.
Professor of Pharmacology and head of BioFarma pharmacology research group at the University of Santiago de Compostela. Leader in the field of Early Drug Discovery at Spanish and European levels, endorsed by the participation in more than 90 research programs as principal investigator, founded by public and private institutions. She has participated actively in the development of 15 NCE that have reached clinical trials in the specific programs of R&D transfer in drug development of different pharmaceutical companies.
Dr. Loza is author of 190 articles in indexed journals in the Journal Citation Report and more than 300 contributions at national and international congresses in Pharmacology, Medicinal Chemistry and Drug Discovery, Coordinator of the Drug Discovery Galician Network, the Drug Discovery Spanish Network of Excellence (REDEFAR) and the ES-OPENSCREEN Network connected to the ERIC EU- OPENSCREEN. She is member of the Board of trustees of Kæertor Foundation, a non for profit foundation for promoting reciprocal transference in open innovation in drug discovery. As an entrepreneur, she has promoted the foundation of three companies (Pharmatools Digital Interactive SL, Allelyus and Oncostellae)
Graduated in Organic Chemistry at the University of Santiago de Compostela (1980) where he also obtained his PhD (1985). Between 1986 and 1988 he worked as a postdoc in the laboratory of Prof. Henry Rapoport, at the University of California, as a Fulbright Scholar.
He is currently Professor of Organic Chemistry at the University of Santiago de Compostela where he leads a research group with a wide range of scientific interests, from organic synthesis to sustainable chemistry and scientific software development. He has extensive experience in technology transfer, noting that in 2004 he participates in the creation of the company MestreLab, where he acts as Director of its Scientific Advisory Board, and in 2018 he co-founded the knowledge-based company Sigillum Knowledge Solutions.
Non Executive Director
Santi Dominguez graduated from University of Santiago de Compostela, Spain, in 1995. After 10 years in different commercial and management roles in the speciality chemicals industry, he moved into technological entrepreneurship. Santi cofounded Mestrelab Research SL, a Spanish scientific software business, in 2004, and managed as CEO its development to a partial 8 figure exit in 2018 and continuous high growth development since then. Simultaneously, he cofounded IMSPEX Diagnostics Ltd, a UK diagnostics and analytical instrumentation company in 2011, in which he has overseen as CEO and Executive Chairman several funding rounds, the acquisition of a German company, GAS GmbH, and the partial sale of IMSPEX to a Chinese corporation, Hanon Instruments Ltd.
Santi is also a seed investor in over a dozen technology projects and has occupied a number of board positions, more notably 9 years on the board of eMolecules Inc, a California chemical e-commerce startup which has developed into a World leader in its vertical. Santi has extensive experience of creating startups and developing them into commercially successful businesses with high exit potential.